首页 > 最新文献

Pathogens and Global Health最新文献

英文 中文
Staphylococcus aureus epidemiology, pathophysiology, clinical manifestations and application of nano-therapeutics as a promising approach to combat methicillin resistant Staphylococcus aureus. 金黄色葡萄球菌的流行病学、病理生理、临床表现及纳米治疗作为对抗耐甲氧西林金黄色葡萄球菌的一种有前途的方法的应用。
IF 4.9 4区 医学 Q1 PARASITOLOGY Pub Date : 2024-05-01 Epub Date: 2023-11-25 DOI: 10.1080/20477724.2023.2285187
Raghad H F Bashabsheh, O'la Al-Fawares, Iyad Natsheh, Roba Bdeir, Rozan O Al-Khreshieh, Hasan H F Bashabsheh

Staphylococcus aureus is a Gram-positive bacterium and one of the most prevalent infectious disease-related causes of morbidity and mortality in adults. This pathogen can trigger a broad spectrum of diseases, from sepsis and pneumonia to severe skin infections that can be fatal. In this review, we will provide an overview of S. aureus and discuss the extensive literature on epidemiology, transmission, genetic diversity, evolution and antibiotic resistance strains, particularly methicillin resistant S. aureus (MRSA). While many different virulence factors that S. aureus produces have been investigated as therapeutic targets, this review examines recent nanotechnology approaches, which employ materials with atomic or molecular dimensions and are being used to diagnose, treat, or eliminate the activity of S. aureus. Finally, having a deeper understanding and clearer grasp of the roles and contributions of S. aureus determinants, antibiotic resistance, and nanotechnology will aid us in developing anti-virulence strategies to combat the growing scarcity of effective antibiotics against S. aureus.

金黄色葡萄球菌是一种革兰氏阳性细菌,是成年人发病和死亡的最普遍的传染病相关原因之一。这种病原体可以引发广泛的疾病,从败血症和肺炎到可能致命的严重皮肤感染。在这篇综述中,我们将提供金黄色葡萄球菌的概述,并讨论广泛的文献流行病学,传播,遗传多样性,进化和抗生素耐药菌株,特别是耐甲氧西林金黄色葡萄球菌(MRSA)。虽然金黄色葡萄球菌产生的许多不同的毒力因子已被研究作为治疗靶点,但本文综述了最近的纳米技术方法,这些方法使用具有原子或分子尺寸的材料,并被用于诊断、治疗或消除金黄色葡萄球菌的活性。最后,对金黄色葡萄球菌决定因子、抗生素耐药性和纳米技术的作用和贡献有了更深入的了解和更清晰的把握,将有助于我们制定抗毒策略,以应对金黄色葡萄球菌有效抗生素日益短缺的问题。
{"title":"<i>Staphylococcus aureus</i> epidemiology, pathophysiology, clinical manifestations and application of nano-therapeutics as a promising approach to combat methicillin resistant <i>Staphylococcus aureus</i>.","authors":"Raghad H F Bashabsheh, O'la Al-Fawares, Iyad Natsheh, Roba Bdeir, Rozan O Al-Khreshieh, Hasan H F Bashabsheh","doi":"10.1080/20477724.2023.2285187","DOIUrl":"10.1080/20477724.2023.2285187","url":null,"abstract":"<p><p><i>Staphylococcus aureus</i> is a Gram-positive bacterium and one of the most prevalent infectious disease-related causes of morbidity and mortality in adults. This pathogen can trigger a broad spectrum of diseases, from sepsis and pneumonia to severe skin infections that can be fatal. In this review, we will provide an overview of <i>S. aureus</i> and discuss the extensive literature on epidemiology, transmission, genetic diversity, evolution and antibiotic resistance strains, particularly methicillin resistant <i>S. aureus</i> (MRSA). While many different virulence factors that <i>S. aureus</i> produces have been investigated as therapeutic targets, this review examines recent nanotechnology approaches, which employ materials with atomic or molecular dimensions and are being used to diagnose, treat, or eliminate the activity of <i>S. aureus</i>. Finally, having a deeper understanding and clearer grasp of the roles and contributions of <i>S. aureus</i> determinants, antibiotic resistance, and nanotechnology will aid us in developing anti-virulence strategies to combat the growing scarcity of effective antibiotics against <i>S. aureus</i>.</p>","PeriodicalId":19850,"journal":{"name":"Pathogens and Global Health","volume":null,"pages":null},"PeriodicalIF":4.9,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11221481/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138441072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Modeling the health impact of increasing vaccine coverage and nonpharmaceutical interventions against coronavirus disease 2019 in Ghana. 在加纳模拟扩大疫苗覆盖面和非药物干预措施对 2019 年冠状病毒疾病的健康影响。
IF 4.9 4区 医学 Q1 PARASITOLOGY Pub Date : 2024-05-01 Epub Date: 2024-02-06 DOI: 10.1080/20477724.2024.2313787
Sylvia K Ofori, Jessica S Schwind, Kelly L Sullivan, Gerardo Chowell, Benjamin J Cowling, Isaac Chun-Hai Fung

Seroprevalence studies assessing community exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Ghana concluded that population-level immunity remained low as of February 2021. Thus, it is important to demonstrate how increasing vaccine coverage reduces the economic and public health impacts associated with SARS-CoV-2 transmission. To that end, this study used a Susceptible-Exposed-Presymptomatic-Symptomatic-Asymptomatic-Recovered-Dead-Vaccinated compartmental model to simulate coronavirus disease 2019 (COVID-19) transmission and the role of public health interventions in Ghana. The impact of increasing vaccination rates and decline in transmission rates due to nonpharmaceutical interventions (NPIs) on cumulative infections and deaths averted was explored under different scenarios. Latin hypercube sampling-partial rank correlation coefficient (LHS-PRCC) was used to investigate the uncertainty and sensitivity of the outcomes to the parameters. Simulation results suggest that increasing the vaccination rate to achieve 50% coverage was associated with almost 60,000 deaths and 25 million infections averted. In comparison, a 50% decrease in the transmission coefficient was associated with the prevention of about 150,000 deaths and 50 million infections. The LHS-PRCC results indicated that in the context of vaccination rate, cumulative infections and deaths averted were most sensitive to vaccination rate, waning immunity rates from vaccination, and waning immunity from natural infection. This study's findings illustrate the impact of increasing vaccination coverage and/or reducing the transmission rate by NPI adherence in the prevention of COVID-19 infections and deaths in Ghana.

对加纳社区接触严重急性呼吸系统综合症冠状病毒 2(SARS-CoV-2)的情况进行的血清流行率评估研究得出结论,截至 2021 年 2 月,人口的免疫力仍然很低。因此,证明提高疫苗覆盖率如何减少与 SARS-CoV-2 传播相关的经济和公共卫生影响非常重要。为此,本研究使用 "易感者-暴露者-无症状者-无症状者-恢复者-死亡者-疫苗接种者 "分区模型模拟加纳 2019 年冠状病毒病(COVID-19)的传播和公共卫生干预措施的作用。在不同情景下,探讨了疫苗接种率的提高和非药物干预(NPIs)导致的传播率下降对累计感染和避免死亡的影响。采用拉丁超立方抽样-部分秩相关系数(LHS-PRCC)来研究结果的不确定性和对参数的敏感性。模拟结果表明,提高疫苗接种率以达到 50%的覆盖率可避免近 60,000 例死亡和 2,500 万例感染。相比之下,传播系数降低 50%,可避免约 15 万人死亡和 5000 万人感染。LHS-PRCC 结果表明,在疫苗接种率的背景下,累积感染和避免死亡对疫苗接种率、疫苗接种的免疫力减弱率和自然感染的免疫力减弱率最为敏感。这项研究的结果说明了在加纳提高疫苗接种覆盖率和/或通过坚持 NPI 降低传播率对预防 COVID-19 感染和死亡的影响。
{"title":"Modeling the health impact of increasing vaccine coverage and nonpharmaceutical interventions against coronavirus disease 2019 in Ghana.","authors":"Sylvia K Ofori, Jessica S Schwind, Kelly L Sullivan, Gerardo Chowell, Benjamin J Cowling, Isaac Chun-Hai Fung","doi":"10.1080/20477724.2024.2313787","DOIUrl":"10.1080/20477724.2024.2313787","url":null,"abstract":"<p><p>Seroprevalence studies assessing community exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Ghana concluded that population-level immunity remained low as of February 2021. Thus, it is important to demonstrate how increasing vaccine coverage reduces the economic and public health impacts associated with SARS-CoV-2 transmission. To that end, this study used a Susceptible-Exposed-Presymptomatic-Symptomatic-Asymptomatic-Recovered-Dead-Vaccinated compartmental model to simulate coronavirus disease 2019 (COVID-19) transmission and the role of public health interventions in Ghana. The impact of increasing vaccination rates and decline in transmission rates due to nonpharmaceutical interventions (NPIs) on cumulative infections and deaths averted was explored under different scenarios. Latin hypercube sampling-partial rank correlation coefficient (LHS-PRCC) was used to investigate the uncertainty and sensitivity of the outcomes to the parameters. Simulation results suggest that increasing the vaccination rate to achieve 50% coverage was associated with almost 60,000 deaths and 25 million infections averted. In comparison, a 50% decrease in the transmission coefficient was associated with the prevention of about 150,000 deaths and 50 million infections. The LHS-PRCC results indicated that in the context of vaccination rate, cumulative infections and deaths averted were most sensitive to vaccination rate, waning immunity rates from vaccination, and waning immunity from natural infection. This study's findings illustrate the impact of increasing vaccination coverage and/or reducing the transmission rate by NPI adherence in the prevention of COVID-19 infections and deaths in Ghana.</p>","PeriodicalId":19850,"journal":{"name":"Pathogens and Global Health","volume":null,"pages":null},"PeriodicalIF":4.9,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11221473/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139692595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genetic diversity and evolutionary dynamics of the Omicron variant of SARS-CoV-2 in Morocco. 摩洛哥 SARS-CoV-2 Omicron 变体的遗传多样性和进化动态。
IF 4.9 4区 医学 Q1 PARASITOLOGY Pub Date : 2024-05-01 Epub Date: 2023-08-27 DOI: 10.1080/20477724.2023.2250942
Safae El Mazouri, Abdelmounim Essabbar, Tarik Aanniz, Rachid Eljaoudi, Lahcen Belyamani, Azeddine Ibrahimi, Mouna Ouadghiri

Among the numerous variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that have been reported worldwide, the emergence of the Omicron variant has drastically changed the landscape of the coronavirus disease (COVID-19) pandemic. Here, we analyzed the genetic diversity of Moroccan SARS-CoV-2 genomes with a focus on Omicron variant after one year of its detection in Morocco in order to understand its genomic dynamics, features and its potential introduction sources. From 937 Omicron genomes, we identified a total of 999 non-unique mutations distributed across 92 Omicron lineages, of which 13 were specific to the country. Our findings suggest multiple introductory sources of the Omicron variant to Morocco. In addition, we found that four Omicron clades are more infectious in comparison to other Omicron clades. Remarkably, a clade of Omicron is particularly more transmissible and has become the dominant variant worldwide. Moreover, our assessment of Receptor-Binding Domain (RBD) mutations showed that the Spike K444T and N460K mutations enabled a clade higher ability of immune vaccine escape. In conclusion, our analysis highlights the unique genetic diversity of the Omicron variant in Moroccan SARS-CoV-2 genomes, with multiple introductory sources and the emergence of highly transmissible clades. The distinctiveness of the Moroccan strains compared to global ones underscores the importance of ongoing surveillance and understanding of local genomic dynamics for effective response strategies in the evolving COVID-19 pandemic.

在全球已报道的严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)的众多变种中,Omicron 变种的出现极大地改变了冠状病毒病(COVID-19)大流行的格局。在此,我们分析了摩洛哥 SARS-CoV-2 基因组的遗传多样性,重点是摩洛哥发现 Omicron 变种一年后的情况,以了解其基因组动态、特征及其潜在的引入源。在 937 个 Omicron 基因组中,我们共发现了 999 个非独特变异,分布在 92 个 Omicron 系中,其中 13 个是摩洛哥特有的。我们的研究结果表明,摩洛哥的 Omicron 变异有多个引入源。此外,我们还发现,与其他 Omicron 支系相比,四个 Omicron 支系的传染性更强。值得注意的是,一个 Omicron 支系的传播性特别强,已成为全球的主要变种。此外,我们对受体结合域(RBD)突变的评估表明,Spike K444T 和 N460K 突变使该支系具有更强的免疫疫苗逃逸能力。总之,我们的分析凸显了摩洛哥 SARS-CoV-2 基因组中 Omicron 变体独特的遗传多样性,它有多个引种来源,并出现了高传播性支系。与全球菌株相比,摩洛哥菌株的独特性强调了持续监测和了解当地基因组动态对于在不断演变的 COVID-19 大流行中采取有效应对策略的重要性。
{"title":"Genetic diversity and evolutionary dynamics of the Omicron variant of SARS-CoV-2 in Morocco.","authors":"Safae El Mazouri, Abdelmounim Essabbar, Tarik Aanniz, Rachid Eljaoudi, Lahcen Belyamani, Azeddine Ibrahimi, Mouna Ouadghiri","doi":"10.1080/20477724.2023.2250942","DOIUrl":"10.1080/20477724.2023.2250942","url":null,"abstract":"<p><p>Among the numerous variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that have been reported worldwide, the emergence of the Omicron variant has drastically changed the landscape of the coronavirus disease (COVID-19) pandemic. Here, we analyzed the genetic diversity of Moroccan SARS-CoV-2 genomes with a focus on Omicron variant after one year of its detection in Morocco in order to understand its genomic dynamics, features and its potential introduction sources. From 937 Omicron genomes, we identified a total of 999 non-unique mutations distributed across 92 Omicron lineages, of which 13 were specific to the country. Our findings suggest multiple introductory sources of the Omicron variant to Morocco. In addition, we found that four Omicron clades are more infectious in comparison to other Omicron clades. Remarkably, a clade of Omicron is particularly more transmissible and has become the dominant variant worldwide. Moreover, our assessment of Receptor-Binding Domain (RBD) mutations showed that the Spike K444T and N460K mutations enabled a clade higher ability of immune vaccine escape. In conclusion, our analysis highlights the unique genetic diversity of the Omicron variant in Moroccan SARS-CoV-2 genomes, with multiple introductory sources and the emergence of highly transmissible clades. The distinctiveness of the Moroccan strains compared to global ones underscores the importance of ongoing surveillance and understanding of local genomic dynamics for effective response strategies in the evolving COVID-19 pandemic.</p>","PeriodicalId":19850,"journal":{"name":"Pathogens and Global Health","volume":null,"pages":null},"PeriodicalIF":4.9,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11221468/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10084452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Beyond gain of function: strengthening oversight of research with potential pandemic pathogens. 超越功能获得:加强对潜在流行病病原体研究的监督。
IF 4.9 4区 医学 Q1 PARASITOLOGY Pub Date : 2024-05-01 Epub Date: 2023-10-04 DOI: 10.1080/20477724.2023.2265627
Gregory D Koblentz, Rocco Casagrande

In 2017, the Department of Health and Human Services adopted a policy, known as the P3CO Framework, to govern proposed research that could enhance the lethality or transmissibility of a potential pandemic pathogen. The prospect of a human-made virus with artificially enhanced lethality and transmissibility has raised serious biosafety and biosecurity concerns. The COVID-19 pandemic has generated new concerns about the risks posed by such research. Even if the origins of the pandemic are presumed or proven to be the result of a natural zoonotic spillover event, the pandemic has placed greater scrutiny on research that could generate pandemic-capable viruses and dramatically illustrated the consequences if such a virus were released from a laboratory. This article assesses the strengths and weaknesses of the P3CO Framework and provides recommendations for strengthening oversight of research with potential pandemic pathogens. The P3CO Framework should be replaced by a national policy that would apply to all relevant research, regardless of the source of funding and be implemented by a new national agency for biorisk management. This new policy would need to be accompanied by a comprehensive analysis of potential pandemic pathogen risks, clear guidance on how to identify research that falls within the scope of the policy, a rigorous process for reviewing the risks and benefits of such research, and criteria for determining the appropriate measures needed to conduct such research safely, securely, and responsibly.

2017年,卫生与公众服务部通过了一项被称为P3CO框架的政策,以管理可能提高潜在大流行病原体致命性或传播性的拟议研究。人工增强致命性和传播性的人造病毒的前景引发了严重的生物安全和生物安保问题。新冠肺炎大流行引发了人们对此类研究带来的风险的新担忧。即使大流行的起源被推测或证明是自然人畜共患外溢事件的结果,但这场大流行对可能产生具有大流行能力的病毒的研究进行了更严格的审查,并戏剧性地说明了如果这种病毒从实验室释放会产生什么后果。本文评估了P3CO框架的优势和劣势,并为加强对潜在流行病病原体研究的监督提供了建议。P3CO框架应被适用于所有相关研究的国家政策所取代,无论资金来源如何,并由一个新的国家生物风险管理机构实施。这项新政策需要对潜在的大流行病原体风险进行全面分析,就如何确定属于该政策范围的研究提供明确指导,审查此类研究的风险和益处的严格程序,以及确定安全、可靠和负责任地进行此类研究所需的适当措施的标准。
{"title":"Beyond gain of function: strengthening oversight of research with potential pandemic pathogens.","authors":"Gregory D Koblentz, Rocco Casagrande","doi":"10.1080/20477724.2023.2265627","DOIUrl":"10.1080/20477724.2023.2265627","url":null,"abstract":"<p><p>In 2017, the Department of Health and Human Services adopted a policy, known as the P3CO Framework, to govern proposed research that could enhance the lethality or transmissibility of a potential pandemic pathogen. The prospect of a human-made virus with artificially enhanced lethality and transmissibility has raised serious biosafety and biosecurity concerns. The COVID-19 pandemic has generated new concerns about the risks posed by such research. Even if the origins of the pandemic are presumed or proven to be the result of a natural zoonotic spillover event, the pandemic has placed greater scrutiny on research that could generate pandemic-capable viruses and dramatically illustrated the consequences if such a virus were released from a laboratory. This article assesses the strengths and weaknesses of the P3CO Framework and provides recommendations for strengthening oversight of research with potential pandemic pathogens. The P3CO Framework should be replaced by a national policy that would apply to all relevant research, regardless of the source of funding and be implemented by a new national agency for biorisk management. This new policy would need to be accompanied by a comprehensive analysis of potential pandemic pathogen risks, clear guidance on how to identify research that falls within the scope of the policy, a rigorous process for reviewing the risks and benefits of such research, and criteria for determining the appropriate measures needed to conduct such research safely, securely, and responsibly.</p>","PeriodicalId":19850,"journal":{"name":"Pathogens and Global Health","volume":null,"pages":null},"PeriodicalIF":4.9,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11221463/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41143189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of the COVID-19 pandemic on malaria in pregnancy indicators in Northern Uganda: a joinpoint regression analysis. 新冠肺炎大流行对乌干达北部妊娠期疟疾指标的影响:联合点回归分析。
IF 4.9 4区 医学 Q1 PARASITOLOGY Pub Date : 2024-05-01 Epub Date: 2023-10-23 DOI: 10.1080/20477724.2023.2273023
Francesco Vladimiro Segala, Jerry Ictho, Mariangela L'Episcopia, Emmanuel Onapa, Elda De Vita, Roberta Novara, Nelson Olung, Valentina Totaro, Lameck Olal, Giulia Patti, Christopher Bingom, Umberto Farina, Roberta Papagni, Caroline Agaro, Davide Fiore Bavaro, James Amone, Giovanni Dall'Oglio, Benedict Ngole, Claudia Marotta, Samuel Okori, Maurizio Zarcone, Joseph Ogwang, Carlo Severini, Peter Lochoro, Giovanni Putoto, Annalisa Saracino, Francesco Di Gennaro

Background: Pregnancy is both a risk factor for P. falciparum infection and development of severe malaria. In low- and middle-income countries, the COVID-19 pandemic severely impacted health systems, including utilization of maternal services. This study aimed to assess trends in delivering malaria in pregnancy-related health-care services before and during COVID-19 in Northern Uganda.

Methods: An interrupted time-series study comparing pre-COVID-19 (January 2018 to April 2020) and COVID-19 (May to December 2021) periods, based on the date the first COVID case was detected. The study involved 30 health facilities in Northern Uganda with 22,650 estimated pregnancies per year, 14% of which took place in hospital. Monthly data were sourced from District routinely collected indicators. Trends were analyzed by joinpoint regression models.

Results: From the onset of the COVID pandemic in Uganda (May 2020), we found a significant reduction in the number of women accessing a fourth antenatal care visit (from APC + 183.5 to + 4.98; p < 0.001) and taking at least three doses of intermittent preventive treatment in pregnancy (IPTp, from APC + 84.28 to -63.12; p < 0.001). However, we found no significant change in the trend of the total number of pregnant women managed as outpatients or hospitalized for malaria, as well as in the number of women attending their first antenatal visit and in the number of institutional deliveries.

Conclusions: In our study, the COVID-19 pandemic significantly reduced access to ANC visits and IPTp uptake. However, the healthcare system maintained its capacity for managing malaria cases, first antenatal visits, and institutional deliveries.Trial registration: This study has been registered on the ClinicalTrials.gov public website on 26 April 2022. ClinicalTrials.gov Identifier: NCT05348746.

背景:妊娠是恶性疟原虫感染和发展为严重疟疾的危险因素。在中低收入国家,新冠肺炎疫情严重影响了卫生系统,包括孕产妇服务的利用。这项研究旨在评估乌干达北部新冠肺炎之前和期间在妊娠相关医疗服务中提供疟疾的趋势。方法:一项中断的时间序列研究,根据发现第一例新冠肺炎病例的日期,比较新冠肺炎之前(2018年1月至2020年4月)和新冠肺炎期间(2021年5月至12月)。这项研究涉及乌干达北部的30家卫生机构,估计每年有22650例妊娠,其中14%在医院进行。月度数据来源于捷运局定期收集的指标。趋势通过连接点回归模型进行分析。结果:自2020年5月乌干达新冠肺炎疫情爆发以来,我们发现接受第四次产前护理的女性人数显著减少(来自APC + 183.5至 + 4.98;p p 结论:在我们的研究中,新冠肺炎大流行显著减少了ANC就诊和IPTp摄入。然而,医疗保健系统保持了管理疟疾病例、首次产前检查和机构分娩的能力。试验注册:本研究已于2022年4月26日在ClinicalTrials.gov公共网站上注册。ClinicalTrials.gov标识符:NCT05348746。
{"title":"Impact of the COVID-19 pandemic on malaria in pregnancy indicators in Northern Uganda: a joinpoint regression analysis.","authors":"Francesco Vladimiro Segala, Jerry Ictho, Mariangela L'Episcopia, Emmanuel Onapa, Elda De Vita, Roberta Novara, Nelson Olung, Valentina Totaro, Lameck Olal, Giulia Patti, Christopher Bingom, Umberto Farina, Roberta Papagni, Caroline Agaro, Davide Fiore Bavaro, James Amone, Giovanni Dall'Oglio, Benedict Ngole, Claudia Marotta, Samuel Okori, Maurizio Zarcone, Joseph Ogwang, Carlo Severini, Peter Lochoro, Giovanni Putoto, Annalisa Saracino, Francesco Di Gennaro","doi":"10.1080/20477724.2023.2273023","DOIUrl":"10.1080/20477724.2023.2273023","url":null,"abstract":"<p><strong>Background: </strong>Pregnancy is both a risk factor for <i>P. falciparum</i> infection and development of severe malaria. In low- and middle-income countries, the COVID-19 pandemic severely impacted health systems, including utilization of maternal services. This study aimed to assess trends in delivering malaria in pregnancy-related health-care services before and during COVID-19 in Northern Uganda.</p><p><strong>Methods: </strong>An interrupted time-series study comparing pre-COVID-19 (January 2018 to April 2020) and COVID-19 (May to December 2021) periods, based on the date the first COVID case was detected. The study involved 30 health facilities in Northern Uganda with 22,650 estimated pregnancies per year, 14% of which took place in hospital. Monthly data were sourced from District routinely collected indicators. Trends were analyzed by joinpoint regression models.</p><p><strong>Results: </strong>From the onset of the COVID pandemic in Uganda (May 2020), we found a significant reduction in the number of women accessing a fourth antenatal care visit (from APC + 183.5 to + 4.98; <i>p</i> < 0.001) and taking at least three doses of intermittent preventive treatment in pregnancy (IPTp, from APC + 84.28 to -63.12; <i>p</i> < 0.001). However, we found no significant change in the trend of the total number of pregnant women managed as outpatients or hospitalized for malaria, as well as in the number of women attending their first antenatal visit and in the number of institutional deliveries.</p><p><strong>Conclusions: </strong>In our study, the COVID-19 pandemic significantly reduced access to ANC visits and IPTp uptake. However, the healthcare system maintained its capacity for managing malaria cases, first antenatal visits, and institutional deliveries.Trial registration: This study has been registered on the ClinicalTrials.gov public website on 26 April 2022. ClinicalTrials.gov Identifier: NCT05348746.</p>","PeriodicalId":19850,"journal":{"name":"Pathogens and Global Health","volume":null,"pages":null},"PeriodicalIF":4.9,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11221465/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49691873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
“The blinding disease”. The history of trachoma in Italians between the 19th and 20th centuries: colonial or national blindness? "致盲疾病"。19 世纪至 20 世纪意大利人患沙眼的历史:是殖民地失明还是民族失明?
IF 3.4 4区 医学 Q2 Medicine Pub Date : 2024-04-21 DOI: 10.1080/20477724.2024.2342623
Mariano Martini, Niccolò Riccardi, Omar Simonetti, Davide Orsini, Francesco Samassa, Alessandra Parodi
Trachoma is one of the oldest known causes of blindness in humans and it is caused by the intracellular Gram-negative bacterium Chlamydia trachomatis serovars A, B, Ba and C. Its transmission has h...
沙眼是人类最古老的致盲原因之一,由细胞内的革兰氏阴性沙眼衣原体 A、B、Ba 和 C 血清菌引起。
{"title":"“The blinding disease”. The history of trachoma in Italians between the 19th and 20th centuries: colonial or national blindness?","authors":"Mariano Martini, Niccolò Riccardi, Omar Simonetti, Davide Orsini, Francesco Samassa, Alessandra Parodi","doi":"10.1080/20477724.2024.2342623","DOIUrl":"https://doi.org/10.1080/20477724.2024.2342623","url":null,"abstract":"Trachoma is one of the oldest known causes of blindness in humans and it is caused by the intracellular Gram-negative bacterium Chlamydia trachomatis serovars A, B, Ba and C. Its transmission has h...","PeriodicalId":19850,"journal":{"name":"Pathogens and Global Health","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140634494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genetic variability of the SARS-CoV-2 JN.1 lineage SARS-CoV-2 JN.1 世系的基因变异性
IF 3.4 4区 医学 Q2 Medicine Pub Date : 2024-04-14 DOI: 10.1080/20477724.2024.2342620
Fabio Scarpa, Massimo Ciccozzi
Published in Pathogens and Global Health (Ahead of Print, 2024)
发表于《病原体与全球健康》(2024 年提前出版)
{"title":"Genetic variability of the SARS-CoV-2 JN.1 lineage","authors":"Fabio Scarpa, Massimo Ciccozzi","doi":"10.1080/20477724.2024.2342620","DOIUrl":"https://doi.org/10.1080/20477724.2024.2342620","url":null,"abstract":"Published in Pathogens and Global Health (Ahead of Print, 2024)","PeriodicalId":19850,"journal":{"name":"Pathogens and Global Health","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140580425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Web-based intervention for improving influenza vaccination in pregnant women: a cost-effectiveness analysis. 改进孕妇流感疫苗接种的网络干预:成本效益分析。
IF 4.9 4区 医学 Q1 PARASITOLOGY Pub Date : 2024-03-01 Epub Date: 2023-10-16 DOI: 10.1080/20477724.2023.2272109
Yingcheng Wang, Ginenus Fekadu, Joyce H S You

A website with vaccine information and interactive social media was reported to improve maternal influenza vaccine uptake. This study aimed to evaluate cost-effectiveness of a web-based intervention on influenza vaccine uptake among pregnant women from the perspective of US healthcare providers. A one-year decision-analytic model estimated outcomes in a hypothetical cohort of pregnant women with: (1) website with vaccine information and interactive social media (intervention group), and (2) usual care (usual care group). Primary measures included influenza infection, influenza-related hospitalization, mortality, direct medical cost, and quality-adjusted life-year (QALY) loss. In base-case analysis, intervention group reduced cost (by USD28), infection (by 28 per 1,000 pregnant women), hospitalization (by 1.226 per 1,000 pregnant women), mortality (by 0.0036 per 1,000 pregnant women), and saved 0.000305 QALYs versus usual care group. Relative improvement of vaccine uptake by the intervention and number of pregnant women in the healthcare system were two influential factors identified in deterministic sensitivity analysis. The intervention was cost-effective in 99.5% of 10,000 Monte Carlo simulations (at willingness-to-pay threshold 50,000 USD/QALY). A website with vaccine information and interactive social media to promote influenza vaccination for pregnant women appears to reduce direct medical costs and gain QALYs from the perspective of US healthcare providers.

据报道,一个提供疫苗信息和互动社交媒体的网站提高了孕妇流感疫苗的接种率。本研究旨在从美国医疗保健提供者的角度评估基于网络的孕妇流感疫苗接种干预的成本效益。一个为期一年的决策分析模型估计了一个假设孕妇队列的结果:(1)带有疫苗信息和互动社交媒体的网站(干预组),以及(2)常规护理(常规护理组)。主要指标包括流感感染、流感相关住院、死亡率、直接医疗费用和质量调整生命年(QALY)损失。在基本病例分析中,与常规护理组相比,干预组降低了成本(减少了28美元)、感染(减少了28/1000名孕妇)、住院治疗(减少了1.226/1000名孕妇)和死亡率(减少了0.0036/1000名孕产妇),并节省了0.000305个QALYs。在确定性敏感性分析中,干预措施对疫苗接种的相对改善和医疗系统中孕妇人数是两个影响因素。在10000次蒙特卡洛模拟中,99.5%的干预具有成本效益(愿意支付50000美元/QALY的阈值)。从美国医疗保健提供者的角度来看,一个提供疫苗信息和互动社交媒体的网站似乎可以降低直接医疗成本,并获得QALYs。
{"title":"Web-based intervention for improving influenza vaccination in pregnant women: a cost-effectiveness analysis.","authors":"Yingcheng Wang, Ginenus Fekadu, Joyce H S You","doi":"10.1080/20477724.2023.2272109","DOIUrl":"10.1080/20477724.2023.2272109","url":null,"abstract":"<p><p>A website with vaccine information and interactive social media was reported to improve maternal influenza vaccine uptake. This study aimed to evaluate cost-effectiveness of a web-based intervention on influenza vaccine uptake among pregnant women from the perspective of US healthcare providers. A one-year decision-analytic model estimated outcomes in a hypothetical cohort of pregnant women with: (1) website with vaccine information and interactive social media (intervention group), and (2) usual care (usual care group). Primary measures included influenza infection, influenza-related hospitalization, mortality, direct medical cost, and quality-adjusted life-year (QALY) loss. In base-case analysis, intervention group reduced cost (by USD28), infection (by 28 per 1,000 pregnant women), hospitalization (by 1.226 per 1,000 pregnant women), mortality (by 0.0036 per 1,000 pregnant women), and saved 0.000305 QALYs versus usual care group. Relative improvement of vaccine uptake by the intervention and number of pregnant women in the healthcare system were two influential factors identified in deterministic sensitivity analysis. The intervention was cost-effective in 99.5% of 10,000 Monte Carlo simulations (at willingness-to-pay threshold 50,000 USD/QALY). A website with vaccine information and interactive social media to promote influenza vaccination for pregnant women appears to reduce direct medical costs and gain QALYs from the perspective of US healthcare providers.</p>","PeriodicalId":19850,"journal":{"name":"Pathogens and Global Health","volume":null,"pages":null},"PeriodicalIF":4.9,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11141307/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41237534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evolution of COVID-19 infection characteristics in a Lebanese cohort of inpatients during different pandemic periods. 不同大流行时期黎巴嫩住院病人队列中 COVID-19 感染特征的演变。
IF 4.9 4区 医学 Q1 PARASITOLOGY Pub Date : 2024-03-01 Epub Date: 2023-07-23 DOI: 10.1080/20477724.2023.2239492
Tony Haykal, Jonathan Mina, Mohamad Fleifel, Hani Dimassi, Janane Nasr, Ahmad Mahdi, Ranime Harb, Ghida El Hout, Elissar Franjieh, Jacques Mokhbat, Anna Farra, Mariana Helou, Rola Husni

This study aims to describe COVID-19 patients characteristics, laboratory and imaging results, and the different outcomes of patients admitted to the Lebanese American University Medical Center-Rizk Hospital over a period of 9 months. In this observational retrospective study, data were obtained from electronic medical records of 491 male and female patients from the ages of 17 to 97. Analysis of the patients was performed in 3 periods: August 2020 to October 20 November 202020 to January 2021 and February 2021 to April 2021 corresponding with 3 waves of newly diagnosed cases during this period. The sample showed a male predominance with an average age of 63. The average hospitalization length was 10.1 days. The majority of patients were discharged to quarantine. The distribution of hospitalized cases was significantly correlated to the monthly distribution of newly COVID-19 cases in Lebanon. There was no significant difference in patient's characteristics between the 3 periods of the study (gender, age, body mass index, smoking, and medical conditions). Clinical presentations of the patients varied between the 3 periods. Similarly, the course and outcome of infection varied. Patients received less oxygen during period 1, while more patients were cured during period 3. This study presents the first Lebanese cohort of COVID-19 patients with their medical background, clinical presentation, laboratory results, radiological findings and course of infection with its outcome. It also shows how the relations between the medical manifestation of the COVID-19 pandemic and the socio-political measures of infection control are deeply intertwined.

本研究旨在描述 COVID-19 患者的特征、实验室和成像结果,以及黎巴嫩美国大学医学中心-里兹克医院在 9 个月内收治的患者的不同结果。在这项观察性回顾研究中,我们从 491 名年龄在 17 岁至 97 岁之间的男女患者的电子病历中获取了数据。对患者的分析分三个阶段进行:2020 年 8 月至 2020 年 10 月 2020 年 11 月至 2021 年 1 月以及 2021 年 2 月至 2021 年 4 月,与这一时期的 3 波新诊断病例相对应。样本显示男性居多,平均年龄为 63 岁。平均住院时间为 10.1 天。大多数患者出院后都接受了隔离治疗。住院病例的分布与黎巴嫩 COVID-19 新发病例的每月分布有明显的相关性。研究的三个阶段在患者特征(性别、年龄、体重指数、吸烟和医疗条件)方面没有明显差异。三个时期的患者临床表现各不相同。同样,感染的过程和结果也各不相同。第 1 期的患者吸氧较少,而第 3 期治愈的患者较多。本研究介绍了黎巴嫩第一批 COVID-19 患者的医学背景、临床表现、实验室结果、放射学检查结果以及感染过程和结果。研究还显示了 COVID-19 大流行病的医学表现与感染控制的社会政治措施之间的关系。
{"title":"Evolution of COVID-19 infection characteristics in a Lebanese cohort of inpatients during different pandemic periods.","authors":"Tony Haykal, Jonathan Mina, Mohamad Fleifel, Hani Dimassi, Janane Nasr, Ahmad Mahdi, Ranime Harb, Ghida El Hout, Elissar Franjieh, Jacques Mokhbat, Anna Farra, Mariana Helou, Rola Husni","doi":"10.1080/20477724.2023.2239492","DOIUrl":"10.1080/20477724.2023.2239492","url":null,"abstract":"<p><p>This study aims to describe COVID-19 patients characteristics, laboratory and imaging results, and the different outcomes of patients admitted to the Lebanese American University Medical Center-Rizk Hospital over a period of 9 months. In this observational retrospective study, data were obtained from electronic medical records of 491 male and female patients from the ages of 17 to 97. Analysis of the patients was performed in 3 periods: August 2020 to October 20 November 202020 to January 2021 and February 2021 to April 2021 corresponding with 3 waves of newly diagnosed cases during this period. The sample showed a male predominance with an average age of 63. The average hospitalization length was 10.1 days. The majority of patients were discharged to quarantine. The distribution of hospitalized cases was significantly correlated to the monthly distribution of newly COVID-19 cases in Lebanon. There was no significant difference in patient's characteristics between the 3 periods of the study (gender, age, body mass index, smoking, and medical conditions). Clinical presentations of the patients varied between the 3 periods. Similarly, the course and outcome of infection varied. Patients received less oxygen during period 1, while more patients were cured during period 3. This study presents the first Lebanese cohort of COVID-19 patients with their medical background, clinical presentation, laboratory results, radiological findings and course of infection with its outcome. It also shows how the relations between the medical manifestation of the COVID-19 pandemic and the socio-political measures of infection control are deeply intertwined.</p>","PeriodicalId":19850,"journal":{"name":"Pathogens and Global Health","volume":null,"pages":null},"PeriodicalIF":4.9,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11141305/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9912188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COVID-19 vaccine acceptance and hesitancy in Indian context: a systematic review and meta-analysis. COVID-19疫苗在印度的接受和犹豫:一项系统综述和荟萃分析
IF 3.4 4区 医学 Q2 Medicine Pub Date : 2024-03-01 Epub Date: 2023-11-20 DOI: 10.1080/20477724.2023.2285184
Sangeeta Dey, Yadlapalli S Kusuma, Shashi Kant, Dewesh Kumar, Retheesh Babu Gopalan, Parikipandla Sridevi, Sumit Aggarwal

Vaccination against COVID-19 is vital for achieving herd immunity, and the Government of India has adopted several strategies to achieve coverage. Vaccine hesitancy was identified as a potential obstacle in combating COVID-19. This study aimed to review the COVID-19 vaccine acceptance and hesitancy, and factors associated with vaccine hesitancy based on studies conducted in Indian populations. The data sources (PubMed, Scopus, and Google Scholar) were searched by following PRISMA guidelines, and the search was done in September 2022. We performed a meta-analysis through a random effect model to estimate pooled hesitancy rate with 95% confidence intervals (CI). A total of 3,339 records were searched, of which 46 studies were found to be eligible for inclusion in the review. The included studies covered 65,551 respondents, 55% were female. Studies reported COVID-19 vaccine acceptance rate of 65.7% in January-February 2021, which increased to 92.8% in May-August 2021. Likewise, the rate of vaccine hesitancy in December 2020 was 37%, dropping to 12.1% through November 2021. The estimated pooled COVID-19 vaccine hesitancy was 31% [95% CI: 27% - 36%, I2 = 99.3%]. Most studies highlighted that fear of the vaccine's side effects, efficacy, and safety were major barriers to vaccine acceptance. However, as the review indicates, it is important to consider and address all factors contributing to vaccine hesitancy.

针对COVID-19的疫苗接种对于实现群体免疫至关重要,印度政府已采取若干战略来实现免疫覆盖。疫苗犹豫被认为是抗击COVID-19的潜在障碍。本研究旨在回顾基于在印度人群中进行的研究的COVID-19疫苗接受和犹豫,以及与疫苗犹豫相关的因素。按照PRISMA指南对数据源(PubMed、Scopus和Google Scholar)进行检索,检索于2022年9月完成。我们通过随机效应模型进行meta分析,以95%置信区间(CI)估计合并犹豫率。共检索了3339项记录,其中46项研究符合纳入本综述的条件。纳入的研究涵盖了65,551名受访者,其中55%为女性。研究报告2021年1 - 2月新冠肺炎疫苗接种率为65.7%,2021年5 - 8月接种率为92.8%。同样,2020年12月的疫苗犹豫率为37%,到2021年11月降至12.1%。估计合计COVID-19疫苗犹豫率为31% [95% CI: 27% - 36%, I2 = 99.3%]。大多数研究强调,对疫苗副作用、有效性和安全性的担忧是疫苗接受的主要障碍。然而,正如审查指出的那样,重要的是考虑和解决导致疫苗犹豫的所有因素。
{"title":"COVID-19 vaccine acceptance and hesitancy in Indian context: a systematic review and meta-analysis.","authors":"Sangeeta Dey, Yadlapalli S Kusuma, Shashi Kant, Dewesh Kumar, Retheesh Babu Gopalan, Parikipandla Sridevi, Sumit Aggarwal","doi":"10.1080/20477724.2023.2285184","DOIUrl":"10.1080/20477724.2023.2285184","url":null,"abstract":"<p><p>Vaccination against COVID-19 is vital for achieving herd immunity, and the Government of India has adopted several strategies to achieve coverage. Vaccine hesitancy was identified as a potential obstacle in combating COVID-19. This study aimed to review the COVID-19 vaccine acceptance and hesitancy, and factors associated with vaccine hesitancy based on studies conducted in Indian populations. The data sources (PubMed, Scopus, and Google Scholar) were searched by following PRISMA guidelines, and the search was done in September 2022. We performed a meta-analysis through a random effect model to estimate pooled hesitancy rate with 95% confidence intervals (CI). A total of 3,339 records were searched, of which 46 studies were found to be eligible for inclusion in the review. The included studies covered 65,551 respondents, 55% were female. Studies reported COVID-19 vaccine acceptance rate of 65.7% in January-February 2021, which increased to 92.8% in May-August 2021. Likewise, the rate of vaccine hesitancy in December 2020 was 37%, dropping to 12.1% through November 2021. The estimated pooled COVID-19 vaccine hesitancy was 31% [95% CI: 27% - 36%, I<sup>2</sup> = 99.3%]. Most studies highlighted that fear of the vaccine's side effects, efficacy, and safety were major barriers to vaccine acceptance. However, as the review indicates, it is important to consider and address all factors contributing to vaccine hesitancy.</p>","PeriodicalId":19850,"journal":{"name":"Pathogens and Global Health","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11141315/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138445762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Pathogens and Global Health
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1